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shown good inhibitory effect.
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Since 1942, when the commercial solvents corporation
launched penicillin, invented by Alexander Fleming, a consid-
erable decrease in the number of deaths caused by bacterial
infections has been noticed. Optimists have even announcedan end to the era of bacterial diseases. However, too frequent,
and frequently improper, applications of antibiotics have re-
sulted in the formation of drug resistant bacteria strains, and
the world has begun to face another problem; that of treating
nosocomial infections (World Health organization(WHO),
2002). Treating infections caused by drug-resistant bacterial
strains constitutes one of the most essential challenges for med-
icine nowadays. Methicillin- and vancomycin-resistant strains
of Staphylococcus aureus are responsible for most infections
of this type (Rachakonda and Cartee, 2004; Plech et al., 2012;
Nathan 2004). In view of this, the search for new antimicrobial
agents continues unabated. In recent decades, problems of mul-
ti-drug resistant microorganisms have reached an alarming le-
vel in many countries around the world. Infections caused by
S388 R. Teja et al.those microorganisms pose a serious challenge to the medical
community and the need for an effective therapy has led to a
search for novel antimicrobial agents. The increasing cases of
microbial resistance pose a major concern to the scientiﬁc com-
munity and have become a threat to the human life worldwide.
Moreover, invasive microbial infections caused by multi-drug-
resistant gram positive bacteria and microbes are difﬁcult to
diagnose and treat (Goossens, 2005). They are the major cause
of morbidity and mortality especially in immune suppressed
and hospital acquired patients (Mathew and Nath, 2009). To
overcome these problems, the development of new and safe
antimicrobial agents with better effectiveness is urgently
required. To this end, one of the best ways to design new anti-
microbial agents is to generate hybrid molecules by combining
two bioactive heterocyclic moieties in a single molecular scaf-
fold. Condensed heterocyclic systems are characterized to have
a signiﬁcant pharmacological activity. So in order to produce
an active compound in our study three different moieties were
fused (like quinoxaline, imidazole and thiadiazole). Quinoxa-
line derivatives have shown various activities like antimicrobial
(Carta et al., 2004), antibacterial (Aguirre et al., 2004), antitu-
bercular (Carta et al., 2004; Jaso et al., 2005), antiprotozoal
(Hui et al., 2006), anti-candida (Carta, 2004, 2003) anti-cancer
(Hazeldine et al., 2005), anti-AIDS (Fonseca et al., 2004) and
anti-inﬂammatory (Mahaney et al., 2006) activities. Quinoxa-
line derivatives have received much attention in recent years
owing to their biological properties. Many scientists have
reported quinoxalinone derivatives as non-classical analogues
of the antifolic agents – methotrexate and trimetrexate (Sanna
et al., 1998). Five membered heterocyclic compounds have
shown various types of biological activities, among them
1,3,4-thiadiazoles are associated with diverse biological activi-
ties, probably by the virtue of –N‚C–S– grouping (Pandey
et al., 1999), some of them possessed antibacterial, antifungal
(Mohan and Kumar, 2001) and anticonvulsant, anti-parkin-
sonism, hypoglycaemic, anti-histaminic, anticancer, anti-
inﬂammatory, anti-asthmatic and antihypertensive activities.
Similarly, 2,5-disubstituted imidazoles also display a wide spec-
trum of activities such as nasal decongestants, antihistamines,
antiprotozoal agents, antiulcers, antidepressants and alpha
adrenergic blocking agents (Hoffer and Grunberg, 1974;
Heeres et al., 1979). During recent years investigations were
carried out on thiadiazoles and imidazolo[2,1-b][1,3,4]thiadiaz-
oles, many of which have found to possess interesting biological
properties like antimicrobial (Gawande and Shingare, 1987;
Mamolo et al., 1996; Gadad et al., 2000; Alireza et al., 2003),
antitubercular (Eclin et al., 2004; Gadad et al., 2004), anti-
inﬂammatory (Mullican et al., 1993; Song et al., 1999), anti-
convulsant (Chapleo et al., 1986; Myer et al., 1988), antihyper-
tensive (Turner et al., 1988; Myers et al., 1988) and anticancer
activities (Chou et al., 2003). In this work the synthesis of fused
heterocyclic compounds is reported with the antimicrobial
activities of a certain quinoxalines fused with imidazo[2,1-b]
[1,3,4]thiadiazoles.2. Materials and methods
2.1. General
All solvents used were of laboratory grade and were obtained
from SD ﬁne chemicals (Mumbai, India), Merck (Mumbai, In-dia) and Loba Chemie. Melting points were determined in
open glass capillary tubes and were uncorrected. Compounds
were routinely checked for their purity on Silica gel G (Merck)
thin layer chromatography (TLC) plates. Iodine chamber and
UV lamp were used for visualization of TLC spots. The IR
spectra were recorded in KBr pellets on (BIO-RAD FTS)
FT-IR spectrophotometer. 1H NMR spectra were recorded
on Bruker DPX-300 NMR spectrometer in CDCl3 using tetra-
methylsilane (TMS) as an internal standard and 13C NMR
spectra were recorded on Bruker 125 MHz spectrometer. The
chemical shifts were reported in ppm scale. Mass spectra were
obtained on a JEOL-SX-102 instrument using electron impact
ionization. Elemental analyses for C, H, and N were per-
formed on a Perkin Elmer model 240C analyser and were with-
in ±0.4% of the theoretical values.2.2. Microorganisms and medium
All the test micro-organism that was taken for the antimicrobial
screening was purchased from the National Chemical Labora-
tory, Pune. The antimicrobial activities for the synthesized com-
pound were done by the paper disc diffusion method. The
compounds were dissolved in DMSO and to ensure that the sol-
vent per se had no effect on bacterial growth or enzymatic activ-
ity, negative control tests were performed using DMSO at the
same concentrations. The antibacterial activity for the synthe-
sized compounds was screened against gram positive (S. aureus
ATCC 9144 and Bacillus cereus ATCC 11778) and Gram-nega-
tive bacteria (Escherichia coli ATCC 25922 and Pseudomonas
aeruginosa ATCC 2853). The antifungal activities of the synthe-
sized compounds were evaluated against two fungi (Aspergillus
niger ATCC 9029 and Aspergillus fumigatus ATCC 46645). The
minimum inhibitory concentrations (MIC) of the compounds
were also determined by using the agar streak dilution method.
All plates were incubated at 37 + 0.5 C for 24 h for antibacte-
rial activity and for antifungal activity they were incubated at
Sabouraud dextrose agar (SDA) for 72 h at 25 C. The zone of
inhibition of compounds wasmeasured using a cm scale. The se-
lected strains were suspended in nutrient agar to give a ﬁnal den-
sity of 5 · 105 cfu/ml.
2.3. Chemistry
2.3.1. General procedure for the synthesis of 2,3-dichloro-6,7-
dinitroquinoxaline (3)
6,7-dintroquinoxaline-2,3-dione 2 (1.62 g, 0.01 mol), freshly
distilled phosphorus oxychloride (6 ml) and dimethyl formam-
ide (0.5 ml) were reﬂuxed with stirring for 90 min. The reaction
mixture was cooled and poured into ice-water with stirring and
the resulting solid was ﬁltered, washed with water, dried and
recrystallized from ethyl acetate and petroleum ether to yield
pure 3. Yield: 78%. m.p. 58 C. IR: (KBr, cm1) 3035 (Ar
CH), 1620 (C‚N), 1321(C–NO2), 741 (C–Cl).
1H NMR
(CDCl3, 300 MHz) d ppm: 7.36 (s, 2H, ArH).
2.3.2. General procedure for the synthesis of 5-substituted-1, 3,
4- thiadiazol-2-amine (4)
A mixture of carboxylic acid (0.01 mol) and thiosemicarbazide
(0.01 mol) in concentrated sulphuric acid (5 ml) was heated un-
der reﬂux on a water bath for 1 h. The resultant mixture was
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It was washed off and washed repeatedly with water. The thi-
adiazoles thus synthesized were recrystallized from ethanol.
2.3.2.1. 5-phenyl-1,3,4-thiadiazol-2-amine (4a). Yield:70%
m.p. 135 C. IR: (KBr, cm1) 3368 (NH), 3035 (CH). 1H
NMR (CDCl3, 300 MHz) d ppm: 4.4 (s, 2H, NH2), 7.34–
7.87 (m, 5H, ArH).
2.3.2.2. 5-(4-aminophenyl)-1,3,4-thiadiazol-2-amine (4b).
Yield:78% m.p. 109 C. IR (KBr, cm1): 3410 (NH), 3012
(CH). 1H NMR (CDCl3, 300 MHz) d ppm: 4.9 (s, 2H, NH2),
6.59–7.27 (m, 4H, ArH).
2.3.2.3. 5-(2-chlorophenyl)-1,3,4-thiadiazol-2-amine (4c).
Yield: 90% m.p. 201 C. IR (KBr, cm1): 3418 (NH), 3016
(CH), 758 (C–Cl). 1H NMR (CDCl3, 300 MHz) d ppm: 4.8
(s, 2H, NH2), 7.34–7.87 (m, 4H, ArH).
2.3.2.4. 5-(2-hydroxyphenyl)-1,3,4-thiadiazol-5-amine (4d).
Yield:85% m.p.55 C. IR (KBr, cm1): 3525 (OH) 3401
(NH), 3008 (CH). 1H NMR (CDCl3, 300 MHz) d ppm: 4.2
(s, 2H, NH2), 7.36–7.85 (m, 4H, ArH)).
2.3.2.5. 5-(2-hydroxy-3,5-dinitrophenyl)-1,3,4-thiadiazol-2-
amine (4e). Yield:75% m.p.104 C. IR (KBr, cm1): 3411
(NH), 3015 (CH). 1H NMR (CDCl3, 300 MHz) d ppm: 4.6
(s, 2H, NH2), 7.14–7.30 (d, 2H, ArH).
2.3.2.6. 5-ethenyl phenyl-1,3,4-thiadiazol-2-amine (4f).
Yield:79% m.p. 111 C. IR (KBr, cm1): 3411 (NH), 3014
(CH). 1H NMR (CDCl3, 300 MHz) d ppm: 4.5 (s, 2H, NH2),
7.24–7.67 (m, 5H, ArH).
2.3.2.7. 5-(triﬂuoromethyl)-1,3,4-thiadiazol-2-amine (4g).
Yield: 85% m.p. 96 C. IR (KBr, cm1) 3414 (NH), 3016
(CH). 1H NMR (CDCl3, 300 MHz) d ppm: 4.8 (s, 2H, NH2).
2.3.3. General procedure for the synthesis of title compound
(5a–5g)
A mixture of 2, 3-dichloro-6,7-dinitro quinoxaline, 3 (1.44 g,
0.005 mol), substituted thiadiazole derivatives 4a-g
(0.005 mol) and sodium acetate (0.82 g, 0.01 mol) was placed
along with 30 ml ethanol in 250 ml RBF. The mixture was re-
ﬂuxed for 5 h and on pouring into ice, precipitate was ob-
tained. It was ﬁltered, dried and recrystallized from suitable
solvents. This procedure and isolation of the compounds gave
materials of good purity, as they were evidenced by the spec-
tral analyses and by TLC. The title compounds were found
to be soluble in dimethyl sulfoxide and dimethylformamide.Table 1 Physicochemical data of the synthesized compounds (5a-5
Compound code R
5a C6H5
5b 4-C6H4 NH2
5c 2-C6H4Cl
5d 2C6H4OH
5e 3,5-C6H2(NO2)2-2-OH
5f C6H5CH‚CH–
5g CF3The physicochemical properties of the synthesized compounds
were given in Table 1.
2.3.4. Spectral data for the synthesized compound (5a-5g)
2.3.4.1. 7,8-dinitro-2-phenyl-1,3,4]thiadiazolo[20,30:2,3]imidazo
[4,5,b]quinoxaline(5a). IR (KBr, cm1) 3041 (Ar CH), 1616
(C‚N), 1606 (C‚C), 1548, 1317 (C–NO2), 1345 (C–N), 651
(C–S). 1H NMR (CDCl3, 300 MHz) d ppm: 7.85–8.34 (M,
7H, Ar CH). 13C NMR (CDCl3, 125 MHz) (ppm) d:115.1,
118.7, 119.2, 120.9, 123.5, 126.2, 132.7, 133.3, 135.5, 141.1.
ESI–MS: MS: m/z 394 (M+). Anal. Cald for C16H7N7O4S:
C, 48.86; H, 1.79; N, 24.93. Found: C, 48.84; H, 1.81; N, 24.91.
2.3.4.2. 7,8-dinitro-2-(4-amino-phenyl)-[1,3,4]thiadiazol-
o[20,30:2,3]imidazo[4,5-b] quinoxaline(5b). IR (KBr,cm1)
3351 (NH), 3039 (Ar CH), 1618 (C‚N), 1596 (C‚C), 1543,
1318 (C–NO2), 1340 (C–N), 697 (C–S).
1H NMR (CDCl3,
300 MHz) d ppm: 3.71 (s, 2H, NH2), 7.83–8.33 (m, 6H, Ar
CH). 13C NMR (CDCl3, 125 MHz) (ppm) d: 105.8, 113.2,
114.1, 119.4, 124.5, 130.2, 131.5, 133.2, 135.4, 140.8. ESI–
MS: MS: m/z 409 (M+). Anal. Cald for C16H8N8O4S: C,
47.06; H, 1.97; N, 27.44. Found: C, 47.04; H, 1.95; N, 27.42.
2.3.4.3. 7,8-dinitro-2-(2-chloro-phenyl)-[1,3,4]thiadiazol-
o[20,30:2,3]imidazo[4,5-b]quinoxaline (5c). IR (KBr, cm1)
3035 (Ar CH), 1617 (C‚N), 1595 (C‚C) 1544, 1320 (C–
NO2), 1346 (C–N), 746 (C–Cl), 696 (C–S).
1H NMR (CDCl3,
300 MHz) d ppm: 7.5–7.97 (m, 6H, Ar CH). 13C NMR
(CDCl3, 125 MHz) (ppm) d: 111.9, 117.5, 118.3, 119.4, 120.3,
122.3, 123.9, 126.6, 130.3, 131.8, 142.1, 164.2. ESI–MS: MS:
m/z 429 (M+). Anal. Cald for C16H6ClN7O4S: C, 44.92; H,
1.41; N, 22.92. Found: C, 44.89; H, 1.42; N, 22.91.
2.3.4.4. 7,8-dinitro-2-(2-hydroxy-phenyl)[1,3,4]thiadiazol-
o[20,30:2,3]imidazo[4,5-b]quinoxaline (5d). IR (KBr, cm1)
3512 (OH), 3041 (Ar CH), 1618 (C‚N), 1586 (C‚C), 1548,
1319 (C–NO2), 1345 (C–N), 685 (C–S).
1H NMR (CDCl3,
300 MHz) d ppm: 5.1 (s, 1H, OH), 7.89–8.37 (m, 6H, Ar
CH). 13C NMR (CDCl3, 125 MHz) (ppm) d: 107.3, 110.3,
113.5, 114.6, 116.3, 118.8, 120.4, 127.8, 129.7, 133.1, 145.6,
163.7, 143.5. ESI–MS: MS: m/z 409 (M+). Anal. Cald for
C16H7N7O5S: C, 46.95; H, 1.72; N, 23.95. Found: C, 46.90;
H, 1.75; N, 23.91.
2.3.4.5. 7,8-dinitro-2-(3,5–dinitro-2-hydroxy-phenyl)-[1,3,4]thi-
adiazolo[20,30:2,3]imidazo[4,5-b]quinoxaline (5e). IR (KBr,
cm1) 3501 (OH), 3045 (Ar CH), 1615 (C‚N), 1584 (C‚C),
1547, 1315 (C–NO2), 1346 (C–N), 697 (C–S).
1H NMR (CDCl3,
300 MHz) d ppm: 5.3 (s, 1H, OH), 7.85–8.3 (m, 4H, Ar CH). 13C
NMR (CDCl3, 125 MHz) (ppm) d: 108.4, 112.6, 118.4, 124.8,g).
Mf Mp % Yield
C16H7N7O4S 102–104 75
C16H8N8O4S 122–125 80
C16H6ClN7O4S 113–116 78
C16H7N7O5S 129–131 77
C16H5N9O9S 119–121 85
C18H9N7O4S 99–102 70
C11H2F3N7O4S 154–156 71
S390 R. Teja et al.125.6, 129.8, 130.4, 132.4, 139.8, 141.8.ESI–MS:MS:m/z499 (M+).
Anal. Cald for C16H5N9O9S: C, 38.49; H, 1.01; N, 25.25. Found: C,
38.47; H, 1.02; N, 25.21.
2.3.4.6. 7,8-dinitro-2-(2-ethenylphenyl)-[1,3,4]thiadiazolo[20,
30:2,3]imidazo[4,5-b]quinoxaline (5f). IR (KBr, cm1) 3031
(Ar CH), 3001 (CH), 1605 (C‚N), 1581 (C‚C), 1538, 1321
(C–NO2), 1325 (C–N), 681 (C–S).
1H NMR (CDCl3,
300 MHz) d ppm: 2.31–2.38 (d, 2H, CH), 7.84–8.37 (m, 7H,
Ar CH). 13C NMR (CDCl3, 125 MHz) (ppm) d: 103.2, 106.8,
114.3, 117.8, 118.3, 118.9, 125.3, 127.6, 130.1, 130.8, 142.8,
148.7. ESI–MS: MS: m/z 419 (M+). Anal. Cald for
C18H9N7O4S: C, 51.55; H, 2.16; N, 23.38. Found: C, 51.57;
H, 2.18; N, 23.39.
2.3.4.7. 7,8-dinitro-2-(triﬂuoromethyl)[1,3,4]thiadiazolo[20,30:
2,3]imidazo[4,5-b]quinoxaline (5g). IR (KBr, cm1) 3028 (Ar
CH), 1615 (C‚N), 1585 (C‚C), 1545, 1323 (C–NO2), 1343
(C–N), 699 (C–S). 1H NMR (CDCl3, 300 MHz) d ppm:
7.34–7.58 (d, 2H, Ar CH). 13C NMR (CDCl3, 125 MHz)
(ppm) d: 109.4, 113.4, 124.8, 128.4, 131.2, 147.2, 142.1. ESI–
MS: MS: m/z 385 (M+). Anal. Cald for C11H2F3N7O4S: C,
34.30; H, 0.52; N, 25.45. Found: C, 34.33; H, 0.49; N, 25.49.
3. Antimicrobial activities
3.1. Paper disc diffusion method
The sterilized (Gillespie et al., 1994) medium (40–50 C) which
was autoclaved at 120 C for 30 min was inoculated (1 ml/
100 ml of medium) with the suspension of the selected micro-Table 2 Disc diffusion method results of the synthesized compound
at 100, 150 and 200 lg/ml.
Compound S. aureus B. cereus E. coli
100 150 200 100 150 200 100 150
5a 16 18 20 12 14 18 16 18
5b 10 14 20 11 12 14 18 20
5c 4 6 10 6 8 12 10 12
5d 10 14 20 10 12 16 14 16
5e 6 8 14 6 10 12 6 8
5f – 8 12 4 6 10 – –
5g – 6 8 6 8 10 – –
Ciproﬂoxacin 26 22 24
Fluconazole – – –
Control – – –
Table 3 MIC (lg/ml) of synthesized compounds (5a–5g).
Compound S. aureus B. cereus E. coli
5a 31.25 15.63 31.25
5b 31.25 15.63 31.25
5c 31.25 >62.5 31.25
5d 7.81 7.81 31.25
5e >62.5 31.25 >62.5
5f >62.5 >62.5 31.25
5g 31.25 31.25 >62.5
Ciproﬂoxacin 15.63 7.81 15.63
Fluconazole – – –organism (matched to McFarland barium sulphate standard)
and poured into a petridish to get a thickness of about 3–
4 mm. The paper impregnated with the test compounds (100,
150 and 200 lg/ml in dimethyl formamide) was placed on
the solidiﬁed medium and were pre-incubated for 1 h at room
temperature. They were incubated at 37 C for 24 and at 25 C
for 72 h for antibacterial and antifungal activities, respectively.
All the observed zone of inhibition was presented in Table 2.
3.2. Minimum inhibitory concentration
All the compounds were taken for MIC determination by
using by the agar streak dilution method (Hawkey and Lewi,
1994). A stock solution containing the synthesized compound
(100 lg/ml) in dimethyl formamide was prepared and speciﬁed
quantities of the test compounds were incorporated in the mol-
ten sterile agar (nutrient agar for antibacterial activity and
Sabouraud’s dextrose agar for antifungal activity) medium
which was solidiﬁed at a depth of 3–4 mm in a petridish. A sus-
pension of 5 · 105 cfu/ml of microorganism was applied to
plates with serially diluted compounds in dimethyl formamide
to be tested and incubated at 37 C for 24 and 25 C for 72 h
for bacteria and fungi, respectively. The observed MIC were
presented in Table 3.
4. Results and discussion
4.1. Chemistry
The synthetic plan for the synthesis of title compound was
shown in Scheme 1. Seven compounds were prepared from thiss and standard reagents (diameter of the zone of inhibition (mm)
P. aeruginosa A. niger A. fumigatus
200 100 150 200 100 150 200 100 150 200
22 14 16 22 14 16 20 14 16 18
22 14 16 20 12 14 18 12 16 20
14 12 14 16 10 12 14 10 12 14
20 12 16 18 12 14 18 10 14 16
10 10 12 16 10 12 14 10 12 14
8 8 10 12 10 12 14 12 14 16
6 6 8 12 8 10 12 6 8 12
22 – –
– 22 26
– – –
P. aeruginosa A. niger A. fumigatus
15.63 31.25 15.63
31.25 31.25 15.63
>62.5 >62.5 >62.5
7.81 31.25 7.81
>62.5 31.25 31.25
31.25 31.25 >62.5
31.25 >62.5 >62.5
7.81 – –
– 7.81 15.63
Scheme 1 Synthesis of intermediates and title compounds.
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NMR, Mass spectral and elemental analyses. The synthesis
was started by using O-phenylene diamine and oxalic acid.
Quinoxaline dione 1 was synthesized on reaction, which is ni-
trated by the nitrating mixture of potassium nitrate and sul-
phuric acid according to the reported procedure (Bhise and
Pawar., 2007) to produce 2. This is further converted to di-
chloro compound 3 by using the treatment of phosphorus oxy-
chloride and dimethyl formamide. Then the ﬁnal compounds
5a–g were synthesized as given in Scheme 1.
IR, 1H NMR, mass spectra and elemental analysis charac-
terize the synthesized compound and they were in accordance
with the assigned structures. The IR spectra of all synthesized
compounds showed some characteristic peaks indicating the
presence of particular groups. Formation of the 2,3-dichloro-
6,7-dinitroquinoxaline ring was conﬁrmed by the presence of
absorption peak at 1620 and 741 cm1 in IR due to the pres-
ence of C–NO2 and C–Cl stretching respectively. The forma-
tions of compounds 4a-g were conﬁrmed by the presence of
absorption peak around 3400 cm1 in IR corresponding to
N–H stretching of NH2. Appearance of a singlet around
3.85 ppm for two protons in its 1H NMR spectra which might
be assigned to the NH2 group also conﬁrms the formation of
4a-g. The IR spectrum of the compounds 5a-g had not shown
the presence of peak at the region of 3400–3300 and near 760–
740 cm1 which conﬁrms that NH and C–Cl were absent in the
molecule and the appearance of M + 2 peaks was observed for
5c in mass spectrum. The proton magnetic resonance spectra
of synthesized compounds were recorded in CDCl3. Thefollowing conclusions can be derived by comparing the 1H
NMR spectra of title compounds:
 No peaks were observed for the presence of NH2 peaks in
the ﬁnal compound
 Only aromatic peaks were observed in the range of 7.34–
8.374.2. Antimicrobial activity
The antimicrobial (antibacterial and antifungal) activities of all
the synthesized compounds were carried out against various
species as discussed in the experimental section using the paper
disc diffusion method. The activities were compared by using
Ciproﬂoxacin (100 lg/ml/disc) and Fluconazole (100 lg/ml/
disc) as standard for antibacterial and antifungal activities
respectively and solvent DMF as a control. The results that
are summarized in Table 2, revealed that among all the com-
pounds 5a, 5b and 5d have good antibacterial and antifungal
activity, whereas compounds 5c, 5e, 5f and 5g have moderate
antibacterial and antifungal activity.
5. Conclusions
Some of thiadiazolo[20,30:2,3]imidazo[4,5-b]quinoxalines were
synthesized from o-phenylenediamine. They were character-
ized by IR, 1H NMR, mass spectroscopy and elemental anal-
ysis. The synthesized compounds were screened against four
antibacterial organisms with two gram positive bacteria like
S. aureus and B. cereus and two Gram-negative bacteria like
E. coli, P. aeruginosa and two antifungal organisms like A. ni-
ger and A. fumigatus. From Table 2, it was found that among
the synthesized compounds, only the unsubstituted and elec-
tron donating group containing molecules has shown better
antimicrobial activity when compared to electron withdrawing
compound on the phenyl group. Of all the synthesized com-
pounds, 5a, 5b and 5d had shown good antibacterial and anti-
fungal activity, while other compound had shown moderate
activity. This shows that compound with the electron donating
group or unsubstituted group was helpful in enhancing the
antimicrobial activity.Acknowledgement
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